Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Ranbaxy Laboratories Stories

2013-05-13 16:28:07

WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Today, the United States government brought to a conclusion an eight-year criminal and civil investigation of Ranbaxy Laboratories Limited, India's largest generic drug company, and Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy Laboratories, Inc., Ranbaxy USA, Inc., and Ohm Laboratories, Inc. ("Ranbaxy"). Ranbaxy has agreed to pay $500 million to resolve allegations of falsifying drug data and systemic manufacturing violations....

2013-04-25 12:28:07

DUBLIN, Ireland, April 25, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013 [http://www.researchandmarkets.com/research/sq6vs2/pharmaleaders ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Sun Shines on Indian Generics Manufacturers India is...

2013-03-05 12:28:51

Enters into an in-licensing business agreement with Alembic PRINCETON, N.J., March 5, 2013 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine Base Extended Release Tablets in the U.S. healthcare system. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the New...

Generic Lipitor Substitute Recalled By Ranbaxy
2012-11-30 10:34:23

Connie K. Ho for redOrbit.com — Your Universe Online New Delhi-based Ranbaxy Laboratories recently announced that they would stop production of Atorvastatin, a product similar to Pfizer Inc.´s Lipitor that focuses on fighting high cholesterol. The company´s decision was prompted by a recent recall by the U.S. Food and Drug Administration (FDA). The voluntary recall covers Atorvastatin tablets at 10mg, 20mg, and 40mg strengths. The tablets were recalled due to the...

2012-11-28 12:27:03

PRINCETON, N.J., Nov. 28, 2012 /PRNewswire/ -- On November 9, 2012, Ranbaxy Inc. initiated a voluntary recall of 41 affected lots of Atorvastatin Calcium Tablets (10 mg, 20 mg and 40 mg) which is a solid oral dosage form, to the retail level. The Company is taking this voluntary action as a precautionary measure due to the fact that we cannot exclude the possibility that the affected lots may contain very small glass particles resembling a fine grain of sand (less than 1 mm in size). This...

2012-11-26 08:25:01

PRINCETON, N.J., Nov. 26, 2012 /PRNewswire/ -- Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the sales and promotion launch of Absorica (Isotretinoin) Capsules, a product that is licensed from Cipher Pharmaceuticals Inc. of Mississauga, Ontario. Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Due to its high lipophilicity, oral absorption of isotretinoin is...

2012-10-09 07:28:02

PRINCETON, N.J., Oct. 9, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has launched the authorized generic cevimeline hydrochloride 30 mg. capsules in the U.S. market, under an agreement with Daiichi Sankyo, Inc. Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently...

2012-08-17 02:21:39

PRINCETON, N.J., Aug. 17, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc. Pioglitazone hydrochloride tablets is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, presently distributed by Takeda Pharmaceuticals America, Inc. under the brand name...

2012-08-02 06:24:32

PRINCETON, N.J., Aug. 2, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) today acknowledged an important, new study released by the Generic Pharmaceutical Association (GPhA) which further demonstrates the vital role played by the generic pharmaceutical industry in lowering prescription costs for consumers and the U.S. health care system. The fourth annual Generic Drug Savings study reveals remarkable reductions in healthcare costs over the past 10 years (from 2002 to 2011). The...

2012-05-29 06:24:38

PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals Inc., RLI is expected to launch Absorica(TM) in the...